Filing Details

Accession Number:
0001104659-22-024375
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-02-16 19:39:48
Reporting Period:
2022-02-14
Accepted Time:
2022-02-16 19:39:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1831915 Cytek Biosciences Inc. CTKB () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1315082 Ra Capital Healthcare Fund Lp 200 Berkeley Street
18Th Floor
Boston MA 02116
Yes No No No
1346824 Ra Capital Management, L.p. 200 Berkeley Street
18Th Floor
Boston MA 02116
Yes No No No
1384859 Peter Kolchinsky C/O Ra Capital Management, L.p.
200 Berkeley Street, 18Th Floor
Boston MA 02116
Yes No No No
1619841 M. Rajeev Shah C/O Ra Capital Management, L.p.
200 Berkeley Street, 18Th Floor
Boston MA 02116
Yes No No No
1825376 Ra Capital Nexus Fund Ii, L.p. 200 Berkeley Street
18Th Floor
Boston MA 02116
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-02-14 166,229 $14.72 9,773,257 No 4 P Indirect See footnotes
Common Stock Acquisiton 2022-02-15 166,200 $14.99 9,939,457 No 4 P Indirect See footnotes
Common Stock Acquisiton 2022-02-16 166,200 $14.98 10,105,657 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
No 4 P Indirect See footnotes
No 4 P Indirect See footnotes
Footnotes
  1. The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established December 14, 2021.
  2. This transaction was executed in multiple trades at prices ranging from $14.26 to $15.21; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  3. These securities include 8,079,766 shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund"), 1,185,767 shares held by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and 507,724 shares held by a separately managed account (the "Account").
  4. This transaction was executed in multiple trades at prices ranging from $14.68 to $15.24; the price reported above reflects the weighted average purchase price.
  5. These securities include 8,245,966 shares held directly by the Fund, 1,185,767 shares held by Nexus Fund II, and 507,724 shares held by the Account.
  6. This transaction was executed in multiple trades at prices ranging from $14.65 to $15.20; the price reported above reflects the weighted average purchase price.
  7. These securities include 8,412,166 shares held directly by the Fund, 1,185,767 shares held by Nexus Fund II, and 507,724 shares held by the Account.
  8. RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.